Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges
Therapeutics and Clinical Risk Management · 2026-11 · Volume 22 · 1-17
DOI: 10.2147/tcrm.s652958 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutics and Clinical Risk Management, 2026-11. Verfasst von Bshra A Alsfouk. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
ORCID-Profile: Bshra A Alsfouk
Zitieren
APA
Alsfouk, B. A. (2026). Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges. Therapeutics and Clinical Risk Management, Volume 22, 1-17. https://doi.org/10.2147/tcrm.s652958
Vancouver
Alsfouk BA. Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges. Therapeutics and Clinical Risk Management. 2026;Volume 22:1-17. doi:10.2147/tcrm.s652958
BibTeX
@article{Alsfouk2026,
author = {Alsfouk, Bshra A},
title = {Clinical Positioning of Selective Serotonin Reuptake Inhibitors as Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Comprehensive Review of Mechanisms, Effectiveness, Tolerability, and Treatment Challenges},
journal = {Therapeutics and Clinical Risk Management},
year = {2026},
volume = {Volume 22},
pages = {1--17},
doi = {10.2147/tcrm.s652958}
}
EUVIMED